Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion

NCT06616766 is registered in ClinicalTrials.gov with Yuhan Corporation as lead sponsor.

NCT NCT06616766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06616766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion
Lead sponsor
Yuhan Corporation
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 2, 2024
Completion date
July 29, 2028
Enrollment
201 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (non-small cell lung cancer), solid tumor